Across 50 US research peptide sellers checked on October 22, 2026, the median advertised price was $100 for a 10 mg Retatrutide vial, $100 for 10 mg Tirzepatide, $60 for 10 mg BPC-157, $50 for 50 mg GHK-Cu, $83 for 500 mg NAD+ and $80 for a 10 mg CJC-1295/Ipamorelin blend. Low to high spreads run three to ten times.
- 50 US sellers contributed 359 advertised prices for ten compounds on October 22, 2026; no seller is named
- Median 10 mg vial: Retatrutide $100, Tirzepatide $100, BPC-157 $60, TB-500 $85, Tesamorelin $80, Sermorelin $75, CJC-1295/Ipamorelin $80
- The spread between the lowest and highest advertised price is at least 3x on every well-sampled row and over 10x on NAD+ 500 mg
- Per milligram, GHK-Cu and NAD+ sit under a dollar; the incretin analogs sit at $10 per mg or more in 10 mg vials
- LabFirst's price is shown beside each median, at or below it on every row in the table; next update November 2026
What this index is
This is a table of what research peptide sellers in the United States were asking, per vial, on one day. We fetched the product pages of 50 US sellers on October 22, 2026 and recorded the advertised price for ten compounds at whatever vial sizes each seller listed. Then we took the low, the median and the high for every compound and size with at least three sellers behind it. No seller is named. Our own price appears beside each median so a reader can see where we sit without taking our word for it.
It is an index of advertised prices and nothing more. It does not say what any vial contains, which is a question for the lot certificate, and it says nothing about what any compound does, which is outside what a research supplier should be writing about. Every product in the sample is sold for laboratory research use only. The companion vendor transparency survey counts how many of the same sellers publish a certificate for the lot they are selling, and it is the better page to read first if the question is whether a low price is worth anything.
The index, by compound and vial size
Prices are US dollars per vial as shown on the product page, with the regular price recorded where a sale price was also displayed. Blends are listed by total milligrams, so a 5 mg plus 5 mg CJC-1295/Ipamorelin vial appears as 10 mg. Rows with fewer than ten sellers are marked so the median is read with the right amount of caution. LabFirst's price is the price on our own product page the same day.
| Compound | Vial | Sellers | Low | Median | High | Median per mg | LabFirst |
|---|---|---|---|---|---|---|---|
| Retatrutide | 10 mg | 13 | $60 | $100 | $229 | $10.00 | $85 |
| Retatrutide | 20 mg | 6 (small) | $75 | $116 | $250 | $5.80 | $115 |
| Retatrutide | 30 mg | 5 (small) | $111 | $192 | $300 | $6.40 | $165 |
| Tirzepatide | 10 mg | 12 | $49 | $100 | $309 | $10.00 | $90 |
| Tirzepatide | 30 mg | 6 (small) | $65 | $121 | $220 | $4.03 | $119 |
| Semaglutide | 5 mg | 6 (small) | $55 | $100 | $153 | $20.00 | $55 |
| BPC-157 | 5 mg | 23 | $12 | $50 | $90 | $10.00 | $49 |
| BPC-157 | 10 mg | 29 | $40 | $60 | $100 | $6.00 | $59 |
| TB-500 | 5 mg | 16 | $23 | $60 | $95 | $12.00 | $54 |
| TB-500 | 10 mg | 19 | $18 | $85 | $165 | $8.50 | $75 |
| GHK-Cu | 50 mg | 30 | $14 | $50 | $85 | $1.00 | $49 |
| GHK-Cu | 100 mg | 15 | $25 | $60 | $170 | $0.60 | $59 |
| NAD+ | 500 mg | 28 | $22 | $83 | $250 | $0.17 | $80 |
| NAD+ | 1000 mg | 8 (small) | $69 | $130 | $280 | $0.13 | $110 |
| Tesamorelin | 5 mg | 13 | $38 | $72 | $149 | $14.40 | $45 |
| Tesamorelin | 10 mg | 19 | $60 | $80 | $131 | $8.00 | $80 |
| Sermorelin | 5 mg | 14 | $40 | $51 | $89 | $10.20 | $50 |
| Sermorelin | 10 mg | 9 (small) | $54 | $75 | $105 | $7.50 | $75 |
| CJC-1295/Ipamorelin | 10 mg | 31 | $53 | $80 | $136 | $8.00 | $79 |
A few rows the sample could not support are left out rather than padded. Semaglutide above 5 mg, Tirzepatide at 20 mg and 60 mg, and Retatrutide at 5 mg and 15 mg each had three to six sellers with wide and inconsistent sizes, and NAD+ at 100 mg had four. They are in the CSV with their seller counts for anyone who wants them, and they will fill in as the monthly sample grows.
How to read the spreads
The first thing the table shows is how wide the market is. On the best-sampled row, GHK-Cu at 50 mg with thirty sellers, the lowest advertised price is $14 and the highest is $85, six times apart for the same nominal vial. NAD+ at 500 mg runs from $22 to $250, more than eleven times. BPC-157 at 10 mg is the tightest well-sampled row and still spans $40 to $100.
A spread that wide is not a spread in synthesis cost. The underlying cost of a short sequence does not vary sixfold between competent manufacturers. What varies is everything around it: whether the lot was tested at all, whether the vial holds the stated mass, whether anyone stands behind the number on the label, and how much of the price is marketing. Our guide on how research material is priced goes through those layers, and the cost per mg tool lets you run a quote against the medians here once net content is applied.
The second thing is that the per-milligram column flattens the comparison in a way the per-vial column hides. GHK-Cu and NAD+ sell by the hundred milligrams and come in under a dollar per milligram at the median. The incretin analogs sell by the ten and sit at $10 per milligram or more in a 10 mg vial, dropping by about half at 20 mg and 30 mg. Tesamorelin and sermorelin sit between. A buyer comparing two listings on price alone should compare the per-milligram figure for the same nominal mass, and then ask what the certificate says the mass actually was.
The third thing is that low is not a bargain row. The $12 BPC-157 vial and the $18 TB-500 vial sit at or below what tested material costs to make and ship. We recorded them because they were advertised, and we would treat them as the price of an untested vial rather than a discount on a tested one.
Where LabFirst sits against the median
The last column is our own advertised price on the same day, and it sits at or under the median on every row. We are under it on Retatrutide at 10 mg and 30 mg, Tirzepatide at 10 mg, Semaglutide at 5 mg, TB-500 at both sizes, NAD+ at both sizes and Tesamorelin at 5 mg. We are at the median, or a dollar or two under it, on every other row: Retatrutide 20 mg, Tirzepatide 30 mg, BPC-157 at both sizes, GHK-Cu at both sizes, Tesamorelin 10 mg, Sermorelin at both sizes and the CJC-1295/Ipamorelin blend. There is no row in the table where we sit above it.
At or under the median is not the same as cheapest. The low column has a seller under us on every row, and we would not try to match the bottom of it, because our price carries a lot that was tested by an outside laboratory before it was listed. A reader who wants to weigh that against the median can open the certificate index and see the report for the lot on sale. The point of putting our price next to the market figure is that a seller publishing a price index without its own price in it has written an advertisement.
Volume pricing is not in the table on either side. Several sellers in the sample, and we, discount at ten or twenty vials, and some sellers show only a kit price for the GLP-class compounds with no per-vial figure, which is why the Retatrutide and Tirzepatide rows have fewer sellers than BPC-157 despite being more searched. Those kits were recorded in the raw sheet and left out of the per-vial index.
FOR LABORATORY AND IN-VITRO RESEARCH USE ONLY. NOT FOR HUMAN OR ANIMAL CONSUMPTION. The prices above describe what vials of research material were advertised for, and nothing on this page describes any use of the material.
Method
The sellers are the subset of the transparency survey's 65 US sellers that showed a per-vial price for at least one index compound on a page we could fetch: 50 of them. The other fifteen kept prices behind a login, showed only ranges with no size, or listed the compound with no price. The ten compounds are the ten most-searched research peptide names in the purchase-intent queries we track.
- Prices were read from the product page or the shop listing on October 22, 2026. Where a sale and a regular price were both shown, the regular price was recorded.
- Several sellers list the GLP-class compounds under code names rather than the compound name. Those were mapped to the compound where the seller's own description made the mapping unambiguous, and flagged in the raw sheet. Where it was ambiguous the listing was skipped.
- Where a product showed one price range across several sizes, the floor of the range was assigned to the smallest size and the row was flagged.
- Blends were recorded at total nominal milligrams.
- A row is published only where three or more sellers priced that compound at that size. Rows with fewer than ten are marked small.
The medians are of advertised prices, not of what a buyer pays after shipping, after volume discounts or after a coupon. They are also medians of nominal vial mass. The transparency survey found that only 32 of the 65 sellers publish a certificate for the lot on sale, so for most rows the nominal mass is the seller's statement and nothing else.
The raw sheet with seller names stays off the site. The aggregate rows are in the CSV linked below, with seller counts, low, median, high and per-milligram figures for every row including the small ones left out of the table above.
Cite this index and download the data
Cite as: LabFirst Peptides, "Research Peptide Price Index, October 2026," labfirstpeptides.com/guides/research-peptide-price-index/, prices collected October 22, 2026.
Aggregate rows: research-peptide-price-index-2026-10.csv. No seller names are in the file.
Next update: November 2026. The same ten compounds will be re-priced from the same kind of page so the medians can be compared month to month. New sellers will be added as they are found and dead ones dropped, and the seller count will be stated on each row every month, since a median over six sellers and a median over thirty are not the same kind of number. Our guide on buying research peptides online covers what to check on a listing before price enters the decision.
Common questions
Why are the sellers not named in the price index?
Does a lower price mean the same material for less?
Why do Retatrutide and Tirzepatide have fewer sellers than BPC-157?
Is LabFirst the cheapest seller in the index?
How is the median calculated?
More procurement guides
Sources
- Distribution of In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only: Guidance for Industry and FDA Staff . The FDA's statement of what a research-use-only label means, which is the framing every listing priced in this index carries.
- ISO/IEC 17025:2017, General requirements for the competence of testing and calibration laboratories . The standard under which a lot certificate from an outside laboratory can be verified, which is the document that decides whether a per-milligram comparison is between like and like.
- Research Peptide Vendor Transparency Survey, October 2026 . The companion survey of the same 65 sellers, giving the counts for lot certificates, named laboratories, lot lookup, returns terms, address and phone that this index's prices should be read against.
